These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 12769792)
1. Particle-based vaccines for HIV-1 infection. Young KR; Ross TM Curr Drug Targets Infect Disord; 2003 Jun; 3(2):151-69. PubMed ID: 12769792 [TBL] [Abstract][Full Text] [Related]
2. Virus-like particles: designing an effective AIDS vaccine. Young KR; McBurney SP; Karkhanis LU; Ross TM Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718 [TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions. Virnik K; Ni Y; Berkower I Vaccine; 2013 Apr; 31(17):2119-25. PubMed ID: 23474312 [TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus-like particles activate multiple types of immune cells. Sailaja G; Skountzou I; Quan FS; Compans RW; Kang SM Virology; 2007 Jun; 362(2):331-41. PubMed ID: 17276476 [TBL] [Abstract][Full Text] [Related]
5. Progress in the development of an HIV-1 vaccine. Letvin NL Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379 [TBL] [Abstract][Full Text] [Related]
6. Replication-defective HIV as a vaccine candidate. Tung FY; Rinaldo CR; Montelaro RC AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1247-52. PubMed ID: 9764908 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and virulence of attenuated vaccinia virus Tian Tan encoding HIV-1 muti-epitope genes, p24 and cholera toxin B subunit in mice. Du S; Wang Y; Liu C; Wang M; Zhu Y; Tan P; Ren D; Li X; Tian M; Yin R; Li C; Jin N J Virol Methods; 2015 Jul; 219():1-9. PubMed ID: 25796990 [TBL] [Abstract][Full Text] [Related]
9. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M J Virol; 2017 May; 91(9):. PubMed ID: 28179536 [TBL] [Abstract][Full Text] [Related]
10. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine. Das AT; Zhou X; Vink M; Klaver B; Berkhout B Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570 [TBL] [Abstract][Full Text] [Related]
11. Live attenuated AIDS viruses as vaccines: promise or peril? Ruprecht RM Immunol Rev; 1999 Aug; 170():135-49. PubMed ID: 10566148 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques. Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675 [TBL] [Abstract][Full Text] [Related]
14. Adenoviruses as vectors for HIV vaccines. Gómez-Román VR; Robert-Guroff M AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567 [TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Girard MP; Osmanov S; Assossou OM; Kieny MP Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747 [TBL] [Abstract][Full Text] [Related]
17. A novel non-integrative single-cycle chimeric HIV lentivector DNA vaccine. Moussa M; Arrode-Brusés G; Manoylov I; Malogolovkin A; Mompelat D; Ishimwe H; Smaoune A; Ouzrout B; Gagnon J; Chebloune Y Vaccine; 2015 May; 33(19):2273-2282. PubMed ID: 25825333 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086 [TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus-1 vaccine design: where do we go now? Wijesundara DK; Jackson RJ; Ramshaw IA; Ranasinghe C Immunol Cell Biol; 2011 Mar; 89(3):367-74. PubMed ID: 20956986 [TBL] [Abstract][Full Text] [Related]
20. AIDS vaccine development: the long and winding road. Garber DA; Feinberg MB AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]